Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings?Zacks Investment Research • 02/23/26
CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?Zacks Investment Research • 01/30/26
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026GlobeNewsWire • 01/29/26
Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?Zacks Investment Research • 01/23/26
CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy?Zacks Investment Research • 01/20/26
Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings?Zacks Investment Research • 01/15/26
Lost Money on CorMedix Inc. (CRMD)? Contact Levi & Korsinsky About Fraud InvestigationNewsfile Corp • 01/14/26
CorMedix Inc. (CRMD) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/09/26
CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business UpdatesGlobeNewsWire • 01/08/26
CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCathGlobeNewsWire • 12/18/25